Paul F. Lizzul is Chief Medical Officer at ANAPTYSBIO, INC (ANAB). They have made 7 open-market trades across 2 companies since 2017, most recently 2026-01-08.
CIK 0001711462
1 open-market purchase totalling $150K since 2017, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ANAB | 45,738 | $2.2M |
| SNNA | 196,488 | $27K |
| Total | $2.2M |
Shares reported on the most recent Form 4, priced at the 2026-01-09 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ANAB | SELL | 2026-01-08 | 2026-01-09 | $44.71 | $163K | +6.3% | +12.1% | +53.9% |
| ANAB | SELL | 2026-01-07 | 2026-01-08 | $45.11 | $101K | +9.2% | +16.8% | +53.3% |
| ANAB | SELL | 2026-01-05 | 2026-01-06 | $43.26 | $183K | +0.1% | +4.9% | +36.8% |
| ANAB | SELL · 10b5-1 | 2025-12-22 | 2025-12-23 | $50.00 | $75K | -12.2% | -5.3% | +25.4% |
| ANAB | SELL · 10b5-1 | 2024-09-23 | 2024-09-24 | $38.67 | $58K | -2.6% | -7.6% | -59.9% |
| ANAB | SELL | 2024-09-16 | 2024-09-17 | $38.93 | $173K | -15.0% | -6.2% | -55.6% |
| ANAB | SELL · 10b5-1 | 2024-08-14 | 2024-08-16 | $40.00 | $80K | +9.5% | +15.3% | -39.9% |
| ANAB | SELL · 10b5-1 | 2024-07-18 | 2024-07-19 | $35.00 | $53K | +1.5% | +6.1% | +2.4% |
| ANAB | SELL | 2024-01-08 | 2024-01-09 | $21.81 | $111K | +3.9% | +1.2% | -9.5% |
| ANAB | SELL | 2023-09-14 | 2023-09-18 | $19.48 | $41K | -6.1% | -3.5% | +2.5% |
| SNNA | BUY | 2017-08-01 | 2017-08-01 | $15.00 | $150K | -5.8% | +19.3% | -9.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.